Moltó J - Search Results

1

[Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy].

Llibre JM, Antela A, Arribas JR, Domingo P, Gatell JM, López-Aldeguer J, Lozano F, Miralles C, Moltó J, Moreno S, Ortega E, Riera M, Rivero A, Villalonga C, Clotet B. Llibre JM, et al. Among authors: molto j. Enferm Infecc Microbiol Clin. 2010 Nov;28(9):615-20. doi: 10.1016/j.eimc.2010.08.004. Enferm Infecc Microbiol Clin. 2010. PMID: 20888082 Review. Spanish.

2

Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.

Negredo E, Moltó J, Burger D, Viciana P, Ribera E, Paredes R, Juan M, Ruiz L, Puig J, Pruvost A, Grassi J, Masmitjà E, Clotet B. Negredo E, et al. Among authors: molto j. AIDS. 2004 Feb 20;18(3):459-63. doi: 10.1097/00002030-200402200-00012. AIDS. 2004. PMID: 15090798

3

Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.

Negredo E, Moltó J, Muñoz-Moreno JA, Pedrol E, Ribera E, Viciana P, Galindos MJ, Miralles C, Burger D, Rodriguez Fumaz C, Puig J, Gel S, Rodríguez E, Videla S, Ruiz L, Clotet B. Negredo E, et al. Among authors: molto j. Antivir Ther. 2004 Jun;9(3):335-42. Antivir Ther. 2004. PMID: 15259896 Clinical Trial.

4

Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).

Negredo E, Moltó J, Burger D, Côté H, Miró O, Ribalta J, Martínez E, Puig J, Ruiz L, Salazar J, López S, Montaner J, Rey-Joly C, Clotet B. Negredo E, et al. Among authors: molto j. J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):47-52. doi: 10.1097/00126334-200501010-00009. J Acquir Immune Defic Syndr. 2005. PMID: 15608524 Clinical Trial.

5

Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects.

Moltó J, Ruiz L, Romeu J, Martínez-Picado J, Negredo E, Tural C, Sirera G, Clotet B. Moltó J, et al. AIDS Res Hum Retroviruses. 2004 Dec;20(12):1283-8. doi: 10.1089/aid.2004.20.1283. AIDS Res Hum Retroviruses. 2004. PMID: 15650419

6

Therapeutic drug monitoring of antiretroviral agents scenario.

Moltó J, Clotet B. Moltó J, et al. J HIV Ther. 2004 Nov;9(4):75-8. J HIV Ther. 2004. PMID: 15731738 Review.

7

Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.

Fumaz CR, Muñoz-Moreno JA, Moltó J, Negredo E, Ferrer MJ, Sirera G, Pérez-Alvarez N, Gómez G, Burger D, Clotet B. Fumaz CR, et al. Among authors: molto j. J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):560-5. doi: 10.1097/01.qai.0000147523.41993.47. J Acquir Immune Defic Syndr. 2005. PMID: 15793366

8

Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.

Hill A, Walmsley S, Clotet B, Molto J. Hill A, et al. Among authors: molto j. HIV Med. 2006 Mar;7(2):67-74. doi: 10.1111/j.1468-1293.2006.00351.x. HIV Med. 2006. PMID: 16420251 Free article. Review.

9

The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy.

Negredo E, Clotet B, Puig J, Pérez-Alvarez N, Ruiz L, Romeu J, Moltó J, Rey-Joly C, Blanco J. Negredo E, et al. Among authors: molto j. AIDS. 2006 Feb 28;20(4):619-21. doi: 10.1097/01.aids.0000210617.90954.0e. AIDS. 2006. PMID: 16470128 Clinical Trial.

10

Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.

Moltó J, Ruiz L, Valle M, Martinez-Picado J, Bonjoch A, Bravo I, Negredo E, Heilek-Sneider GM, Clotet B. Moltó J, et al. Antivir Ther. 2006;11(1):47-51. Antivir Ther. 2006. PMID: 16518959 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

281 results

Search Page